Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Immune checkpoint inhibitors (ICIs) are a class of medications that are now standard in the treatment of melanoma. These are standard therapy for melanoma, but long-term side effects on disease in the heart arteries is poorly understood. In this study, melanoma patients receiving ICIs for the first time will undergo a coronary computed tomography angiography (CCTA) scan. CCTA results will be analyzed by the FDA-approved Cleerly TM image analysis pipeline. Patients with disease in their heart arteries will be randomized to usual care or aggressive lipid lowering therapy. Those in the aggressive lipid lowering therapy arm will be seen by a cardiologist and placed on standard lipid lowering medications with a goal of achieving an LDL-C ≤ 55mg/dL. Follow-up CCTA scans will occur at 12-month and 24-month timepoints. The primary outcome of interest will be differences in LDL-C levels between the two arms at the 12-month timepoint. The secondary outcome of interest will be the differences in total plaque volume between the two arms at the 12-month timepoint.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek: mężczyźni od 55 lat lub kobiety od 65 lat
- •Postawiona diagnoza czerniak bez wcześniejszego leczenia immunoterapią
- •Planowanie rozpoczęcia immunoterapii jako standardowe leczenie nowotworu
- •Widoczne złogi tłuszczu w tętnicach serca na wstępnym badaniu serca
- •Zgoda na uczestnictwo w badaniu i dostępność na cały jego czas trwania
✗ Disqualifies
- •Wcześniejszy zawał serca, udar mózgu lub zabiegi na naczyniach sercowych
- •Alergia na kontrast radiologiczny lub problemy z nią związane
- •Poważne problemy z funkcją nerek
- •Zaburzenia rytmu serca ze źle kontrolowanym tempem pracy serca
- •Nieustalność hemodynamiczna lub niestabilność krążenia
- •Waga powyżej 400 funtów (181 kg)
- •Rak tarczycy w ciągu ostatnich 5 lat lub planowana radioaktywna terapia jodu
- •Ciąża lub niemożność wstrzymania oddechu na ponad 10 sekund
Simplified criteria — AI translation
Trial details
- Minimum age
- 55 Years
- Last updated (source)
- August 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Colorado Hospital
Aurora, United States
Trial contact
Zackry Morgan
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.